Promising Indications, Gene Editing Innovations Driving The Future Of iPSC Therapies

In this part of our discussion during the Cell & Gene Live, Unlocking the Potential of iPSC Therapies in Regenerative Medicine, Julie Allickson, Ph.D., Chief Technology Officer at Mayo Clinic's Center for Regenerative Biotherapeutics and Erin Kimbrel, Ph.D., Head of Cell & Gene Therapy Research at Astellas agree that ophthalmology, neurodegenerative diseases (such as Parkinson’s and Alzheimer’s), type 1 diabetes, and cardiovascular conditions are among the most promising areas for iPSC-based therapies over the next 3–5 years.